Sep 10, 2012, 10.56 AM | Source: Moneycontrol.com
Shares of Cipla, a drug producer, touched a fresh 52-week high of Rs 395.45 on Monday and rose for the second consecutive session after the company won patent case against Roche.
Roche had filed suit against Cipla on drug Tarceva in 2008. Delhi HC said Cipla’s product Erlocip could be marketed.
At 10:49 hours IST, the share was trading at Rs 392.00, up 0.32% with volumes of 93,700 equity shares.
On Saturday, the share jumped 2.65% to close at Rs 390.75. Market capitalisation of the company currently stands at Rs 31,474.52 crore.
Pragmatic compulsory licensing policy is needed to
As per Cipla's co-exclusive agreement with SII, th
Centrum is bullish on Cipla has recommended buy ra
Cipla will be falling back on its core strengths i
ICICI Direct recommended hold rating on Cipla with